NASDAQ:KMDA - Kamada Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.60 -0.23 (-3.95 %)
(As of 03/25/2019 04:00 PM ET)
Previous Close$5.83
Today's Range$5.53 - $5.75
52-Week Range$4.35 - $6.45
Volume81,669 shs
Average Volume85,170 shs
Market Capitalization$225.46 million
P/E Ratio10.18
Dividend YieldN/A
Beta1.18
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency. It also provides KamRAB for prophylaxis of rabies disease; KamRho (D) IM to treat prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus, as well as human transferrin that is used as a cultural medium for diagnostic assays and cell cultures. In addition, Kamada Ltd. provides Heparin sodium injection to treat thrombo-embolic disorders; Albumin and Albumin 4% for maintenance of blood plasma; and coagulation factors comprising Factor VIII and Factor IX, as well as IXIARO vaccine. Its products in pipeline are G1-AAT (IV) for graft versus host disease and L1-AAT (1V) for lung transparent, which are in Phase II stage; and D1-AAT (IV) for type-1 diabetes, Inhaled AAT for AAT deficiency, and AAT (liquid) for lung preservation and recombinant AAT, which are in early stage development. Further, the company distributes respiratory products, including Bramitob to manage chronic pulmonary infection and FOSTER for the treatment of asthma; and immunoglobulins comprising IVIG 5% for the treatment of various immunodeficiency-related conditions; Varitect, a varicella zoster immunoglobulin; Zutectra and Hepatect CP for prevention of hepatitis B virus; and Megalotect, a CMV immunoglobulin. It markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceutical Company Limited; PARI GmbH; and Kedrion S.p.A. Kamada Ltd. was founded in 1990 and is headquartered in Rehovot, Israel.

Receive KMDA News and Ratings via Email

Sign-up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KMDA
CUSIPN/A
Phone972-8940-6472

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.47 million
Cash Flow$0.6202 per share
Book Value$2.79 per share

Profitability

Net Income$22.30 million

Miscellaneous

Employees408
Market Cap$225.46 million
Next Earnings Date5/21/2019 (Estimated)
OptionableNot Optionable

Kamada (NASDAQ:KMDA) Frequently Asked Questions

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings results on Tuesday, February, 12th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.29. The biotechnology company had revenue of $48.21 million for the quarter. Kamada had a return on equity of 22.74% and a net margin of 19.48%. View Kamada's Earnings History.

When is Kamada's next earnings date?

Kamada is scheduled to release their next quarterly earnings announcement on Tuesday, May 21st 2019. View Earnings Estimates for Kamada.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2019 earnings guidance on Tuesday, February, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $125-130 million, compared to the consensus revenue estimate of $127.82 million.

What price target have analysts set for KMDA?

1 Wall Street analysts have issued 12 month price targets for Kamada's shares. Their forecasts range from $11.00 to $11.00. On average, they expect Kamada's stock price to reach $11.00 in the next year. This suggests a possible upside of 96.4% from the stock's current price. View Analyst Price Targets for Kamada.

What is the consensus analysts' recommendation for Kamada?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kamada.

Has Kamada been receiving favorable news coverage?

News coverage about KMDA stock has trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kamada earned a news sentiment score of -1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.

Who are some of Kamada's key competitors?

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Zoetis (ZTS) and Gran Tierra Energy (GTE).

Who are Kamada's key executives?

Kamada's management team includes the folowing people:
  • Mr. Amir London, Chief Exec. Officer (Age 50)
  • Mr. Chaime Orlev, Chief Financial Officer (Age 49)
  • Mr. Eran Nir, VP of Operations & Plant Mang. (Age 46)
  • Mr. David Tsur, Co-Founder & Active Deputy Chairman (Age 68)
  • Dr. Naveh Tov M.D., Ph.D., VP of Clinical Devel. & Medical Director for Pulmonary Diseases (Age 55)

Who are Kamada's major shareholders?

Kamada's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (1.66%), Altshuler Shaham Ltd (0.95%), Ibex Investors LLC (0.76%), ETF Managers Group LLC (0.13%), Norges Bank (0.11%) and Ramsey Quantitative Systems (0.09%).

Which institutional investors are selling Kamada stock?

KMDA stock was sold by a variety of institutional investors in the last quarter, including Altshuler Shaham Ltd and Macquarie Group Ltd..

Which institutional investors are buying Kamada stock?

KMDA stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, ETF Managers Group LLC, Norges Bank, Ibex Investors LLC and Ramsey Quantitative Systems.

How do I buy shares of Kamada?

Shares of KMDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.60.

How big of a company is Kamada?

Kamada has a market capitalization of $225.46 million and generates $114.47 million in revenue each year. The biotechnology company earns $22.30 million in net income (profit) each year or $0.55 on an earnings per share basis. Kamada employs 408 workers across the globe.

What is Kamada's official website?

The official website for Kamada is http://www.kamada.com.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The biotechnology company can be reached via phone at 972-8940-6472 or via email at [email protected]


MarketBeat Community Rating for Kamada (NASDAQ KMDA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  391
MarketBeat's community ratings are surveys of what our community members think about Kamada and other stocks. Vote "Outperform" if you believe KMDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KMDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: How is inflation measured?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel